36.46 0.00 (0.00%)
After hours: 4:32PM EDT
|Bid||36.38 x 46000|
|Ask||36.51 x 41800|
|Day's range||36.21 - 36.58|
|52-week range||32.32 - 39.43|
|PE ratio (TTM)||10.13|
|Earnings date||31 Jul 2018|
|Forward dividend & yield||1.36 (3.74%)|
|1y target est||39.86|
Pfizer Inc (NYSE:PFE) is trading with a trailing P/E of 9.9x, which is lower than the industry average of 24x. Although some investors may jump to the conclusion that thisRead More...
Amgen (AMGN) gets approval from the European Commission to add overall survival (OS) data from the TOWER study on the label of its leukemia drug, Blincyto.
Allergan (AGN), a leading specialty pharmaceutical company, is focused on developing, manufacturing, and commercializing pharmaceutical and biologic products.
Another quote used by Walsh, this one from Cindy Pearson of the National Women’s Health Network, claims that “Osteopenia is disease-mongering plain and simple.” Osteopenia is a term used to describe bone-thinning and is considered to be the mid-point between healthy bone and osteoporosis. Is osteopenia (bone-thinning) a disease?
Sarepta (SRPT) shares skyrocket on better-than-expected results from an early-stage study, evaluating its gene therapy as a treatment for DMD patients.
The FDA accepts Myriad Genetics' (MYGN) supplementary premarket approval (sPMA) application for BRACAnalysis CDx to identify the best responders to Pfizer's PARP inhibitor, talazoparib.
Verizon was the only DJIA member trading significantly in the green on Tuesday. Deutsche Bank upgraded the wireless maker, saying shares were cheap.
An experimental gene therapy appeared to dramatically increase the production of a muscle-making protein in three young boys with Duchenne muscular dystrophy, a deadly and irreversible disease, according to results being presented by the drugmaker Sarepta Therapeutics at an investor event this morning. “We think this has huge implications for the treatment of this disease,” says Jerry R. Mendell, the principal investigator in the Center for Gene Therapy at the Research Institute of Nationwide Children’s Hospital, who is leading the study for Sarepta. “Being in this field doing clinical research for many years, I learned to be cautious,” says Ron Crystal, chairman of genetic medicine at Weill Cornell Medicine.
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 31, 2018. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2018 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors.
On June 18, Myriad Genetics (MYGN) announced that the FDA accepted its supplementary premarket approval (or sPMA) application for BRACAnalysis CDx, a companion diagnostic with Pfizer’s (PFE) talazoparib, a PARP (poly ADP ribose polymerase) inhibitor. Pfizer has already filed a new drug application (or NDA) for the approval of talazoparib. The FDA has granted Pfizer’s NDA for talazoparib “priority review” status and provided a Prescription Drug User Fee Act action date of December 2018.
Consumer DNA genetic testing kits are a booming business, and the biggest risk isn't necessarily uncovering a health scare; it's what these companies may do, or be forced to do, with your genetic data.
ViiV Healthcare, which is majority-owned by GlaxoSmithKline and has Pfizer Inc. and Shionogi as shareholders, reported on Thursday positive early results from two late-stage trials testing its two-drug regimen in patients new to HIV treatment relative to a three-drug regimen. GlaxoSmithKline shares rose 2.4% in premarket trade on Thursday after the news. It plans to file for regulatory approvals of the two-drug regimen, composed of the drugs dolutegravir and lamivudine, later this year, and also has plans to present full results at an upcoming scientific meeting.
Let’s be honest: with an income stream like that, backed by household names like Pfizer and AT&T—more on these two stocks below—you’d leap at the chance, right? Funny thing is, for a brief, shining moment in the not-so-distant past (early March 2009), many blue chips actually did deliver payouts of 7%, 10% and more. You needed nerves of steel to plunge in while everyone else was sprinting from the worst market crash since 1929.
Dividends play a key role in compounding returns over time and can form a large part of our portfolio return. Pfizer Inc (NYSE:PFE) has returned to shareholders over the pastRead More...
Pfizer Inc. announced today it will extend its donation of the antibiotic Zithromax® (azithromycin) to the International Trachoma Initiative through 2025, building on the company’s 20-years of work to help eliminate the world’s leading infectious cause of blindness. Approximately 163 million people are at risk of developing the disease and this recommitment ensures that Pfizer, through the International Trachoma Initiative (ITI), will continue to provide trachoma endemic countries with donated antibiotics that are a critical component of the global strategy to eliminate this neglected tropical disease (NTD). Pfizer’s continued donation program will help accelerate significant progress made in the last decade to reduce trachoma through increased donations, resulting in a roughly 50 percent decrease in the number of people at risk of trachoma worldwide today compared to 2011.
December 4, 2006 proved to be a fateful day for Pfizer–the day when it announced that the highly touted cholesterol modifying drug, torcetrapib, was being dropped from development. This drug had potent cholesterol modifying properties: doubling a heart patient’s HDL-c while simultaneously lowering LDL-c by 20% (on top of Lipitor’s 40% LDL-c lowering effect). When patients took torcetrapib in combination with Lipitor, their lipoprotein levels essentially normalized, results that were unprecedented.
Whether it's a steady source of income, capital appreciation to grow your nest egg, or both, these three dividend stocks look like smart choices.
On June 7, Pfizer (PFE) announced that the FDA and the European Medicines Agency (or EMA) provided updates on the regulatory submissions of Talazoparib for the treatment of locally advanced or metastatic breast cancer. In this article, we’ll examine the drug, regulatory submissions, and clinical trials related to the drug.